APO Research
Talk to an analyst

APO RESEARCH · REPORT

Oral Anti-HBV Drugs

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Oral Anti-HBV Drugs Market Outlook and Growth Opportunities 2026

29 December 2025211 pages

Choose your research edition.

Industry ResearchOral Anti-HBV Drugs Industry Research Report 2026143 pages · $2,950 USDIndustry Growth & TrendsGlobal Oral Anti-HBV Drugs Industry Growth and Trends Forecast to 2032124 pages · $3,450 USDMarket StructureGlobal Oral Anti-HBV Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Oral Anti-HBV Drugs Market Outlook and Growth Opportunities 2026211 pages · $4,250 USDMarket Analysis & ForecastGlobal Oral Anti-HBV Drugs Market Analysis and Forecast 2026-2032219 pages · $4,950 USD

Market perspective

The global Oral Anti-HBV Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Oral Anti-HBV Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Oral Anti-HBV Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Oral Anti-HBV Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Oral Anti-HBV Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Oral Anti-HBV Drugs market include Zhongfu Pharmaceutical, Chia Tai Tianqing Pharmaceutical, Easton Biopharmaceuticals, YaoPharma, Tianjin Yaowu Academe Pharmaceutical Industry, Sichuan Kelun Pharmaceutical, Shanghai Desano Pharmaceutical, Qianjin Pharmaceutical and Qilu Pharmaceutical, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Oral Anti-HBV Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Oral Anti-HBV Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Oral Anti-HBV Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Oral Anti-HBV Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Oral Anti-HBV Drugs Segment by Company

Zhongfu Pharmaceutical

Chia Tai Tianqing Pharmaceutical

Easton Biopharmaceuticals

YaoPharma

Tianjin Yaowu Academe Pharmaceutical Industry

Sichuan Kelun Pharmaceutical

Shanghai Desano Pharmaceutical

Qianjin Pharmaceutical

Qilu Pharmaceutical

Jiangxi Qingfeng Pharmaceutical

Fujian Cosunter pharmaceutical

Chengdu Brilliant Pharmaceutical

Cisen Pharmaceutical

Beijing SL Pharmaceutical

Beijing Baiao Pharmaceutical

Anhui Biochem

Viatris

Towa Pharmaceutical

Teva

Sigmapharm Laboratories

Sandoz Pharmaceuticals

GSK

Gilead Sciences

Camber Pharmaceuticals

Bristol Myers Squibb

Apotex

Oral Anti-HBV Drugs Segment by Type

Adefovir

Entecavir

Lamivudine

Telbivudine

Tenofovir

Other

Oral Anti-HBV Drugs Segment by Application

Hospital and Clinic

Pharmacy

Other

Oral Anti-HBV Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Oral Anti-HBV Drugs status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Oral Anti-HBV Drugs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Oral Anti-HBV Drugs significant trends, drivers, influence factors in global and regions.

6. To analyze Oral Anti-HBV Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Oral Anti-HBV Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Oral Anti-HBV Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Oral Anti-HBV Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Oral Anti-HBV Drugs market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Oral Anti-HBV Drugs industry.

Chapter 3: Detailed analysis of Oral Anti-HBV Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Oral Anti-HBV Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Oral Anti-HBV Drugs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Oral Anti-HBV Drugs Industry Trends Table 2. Oral Anti-HBV Drugs Industry Drivers Table 3. Oral Anti-HBV Drugs Industry Opportunities and Challenges Table 4. Oral Anti-HBV Drugs Industry Restraints Table 5. Global Oral Anti-HBV Drugs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Oral Anti-HBV Drugs Revenue Share by Company (2021-2026) Table 7. Global Oral Anti-HBV Drugs Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Oral Anti-HBV Drugs Sales Volume Share by Company (2021-2026) Table 9. Global Oral Anti-HBV Drugs Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Oral Anti-HBV Drugs Company Ranking, (2024-2026) & (USD Million) Table 11. Global Oral Anti-HBV Drugs Key Company Manufacturing Base & Headquarters Table 12. Global Oral Anti-HBV Drugs Company, Product Type & Application Table 13. Global Oral Anti-HBV Drugs Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Oral Anti-HBV Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Adefovir Table 18. Significant Companies of Entecavir Table 19. Significant Companies of Lamivudine Table 20. Significant Companies of Telbivudine Table 21. Significant Companies of Tenofovir Table 22. Significant Companies of Other Table 23. Global Oral Anti-HBV Drugs Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 24. Global Oral Anti-HBV Drugs Sales Volume by Type (2021-2026) & (K Units) Table 25. Global Oral Anti-HBV Drugs Sales Volume by Type (2027-2032) & (K Units) Table 26. Global Oral Anti-HBV Drugs Sales Volume Share by Type (2021-2026) Table 27. Global Oral Anti-HBV Drugs Sales Volume Share by Type (2027-2032) Table 28. Global Oral Anti-HBV Drugs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Oral Anti-HBV Drugs Sales Value by Type (2021-2026) & (US$ Million) Table 30. Global Oral Anti-HBV Drugs Sales Value by Type (2027-2032) & (US$ Million) Table 31. Global Oral Anti-HBV Drugs Sales Value Share by Type (2021-2026) Table 32. Global Oral Anti-HBV Drugs Sales Value Share by Type (2027-2032) Table 33. Significant Companies of Hospital and Clinic Table 34. Significant Companies of Pharmacy Table 35. Significant Companies of Other Table 36. Global Oral Anti-HBV Drugs Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 37. Global Oral Anti-HBV Drugs Sales Volume by Application (2021-2026) & (K Units) Table 38. Global Oral Anti-HBV Drugs Sales Volume by Application (2027-2032) & (K Units) Table 39. Global Oral Anti-HBV Drugs Sales Volume Share by Application (2021-2026) Table 40. Global Oral Anti-HBV Drugs Sales Volume Share by Application (2027-2032) Table 41. Global Oral Anti-HBV Drugs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 42. Global Oral Anti-HBV Drugs Sales Value by Application (2021-2026) & (US$ Million) Table 43. Global Oral Anti-HBV Drugs Sales Value by Application (2027-2032) & (US$ Million) Table 44. Global Oral Anti-HBV Drugs Sales Value Share by Application (2021-2026) Table 45. Global Oral Anti-HBV Drugs Sales Value Share by Application (2027-2032) Table 46. Global Oral Anti-HBV Drugs Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 47. Global Oral Anti-HBV Drugs Sales by Region (2021-2026) & (K Units) Table 48. Global Oral Anti-HBV Drugs Sales Market Share by Region (2021-2026) Table 49. Global Oral Anti-HBV Drugs Sales by Region (2027-2032) & (K Units) Table 50. Global Oral Anti-HBV Drugs Sales Market Share by Region (2027-2032) Table 51. Global Oral Anti-HBV Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 52. Global Oral Anti-HBV Drugs Sales Value by Region (2021-2026) & (US$ Million) Table 53. Global Oral Anti-HBV Drugs Sales Value Share by Region (2021-2026) Table 54. Global Oral Anti-HBV Drugs Sales Value by Region (2027-2032) & (US$ Million) Table 55. Global Oral Anti-HBV Drugs Sales Value Share by Region (2027-2032) Table 56. Global Oral Anti-HBV Drugs Market Average Price (US$/Unit) by Region (2021-2026) Table 57. Global Oral Anti-HBV Drugs Market Average Price (US$/Unit) by Region (2027-2032) Table 58. Global Oral Anti-HBV Drugs Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 59. Global Oral Anti-HBV Drugs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 60. Global Oral Anti-HBV Drugs Sales by Country (2021-2026) & (K Units) Table 61. Global Oral Anti-HBV Drugs Sales Market Share by Country (2021-2026) Table 62. Global Oral Anti-HBV Drugs Sales by Country (2027-2032) & (K Units) Table 63. Global Oral Anti-HBV Drugs Sales Market Share by Country (2027-2032) Table 64. Global Oral Anti-HBV Drugs Sales Value by Country (2021-2026) & (US$ Million) Table 65. Global Oral Anti-HBV Drugs Sales Value Market Share by Country (2021-2026) Table 66. Global Oral Anti-HBV Drugs Sales Value by Country (2027-2032) & (US$ Million) Table 67. Global Oral Anti-HBV Drugs Sales Value Market Share by Country (2027-2032) Table 68. Zhongfu Pharmaceutical Company Information Table 69. Zhongfu Pharmaceutical Business Overview Table 70. Zhongfu Pharmaceutical Oral Anti-HBV Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. Zhongfu Pharmaceutical Oral Anti-HBV Drugs Product Portfolio Table 72. Zhongfu Pharmaceutical Recent Development Table 73. Chia Tai Tianqing Pharmaceutical Company Information Table 74. Chia Tai Tianqing Pharmaceutical Business Overview Table 75. Chia Tai Tianqing Pharmaceutical Oral Anti-HBV Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Chia Tai Tianqing Pharmaceutical Oral Anti-HBV Drugs Product Portfolio Table 77. Chia Tai Tianqing Pharmaceutical Recent Development Table 78. Easton Biopharmaceuticals Company Information Table 79. Easton Biopharmaceuticals Business Overview Table 80. Easton Biopharmaceuticals Oral Anti-HBV Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Easton Biopharmaceuticals Oral Anti-HBV Drugs Product Portfolio Table 82. Easton Biopharmaceuticals Recent Development Table 83. YaoPharma Company Information Table 84. YaoPharma Business Overview Table 85. YaoPharma Oral Anti-HBV Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. YaoPharma Oral Anti-HBV Drugs Product Portfolio Table 87. YaoPharma Recent Development Table 88. Tianjin Yaowu Academe Pharmaceutical Industry Company Information Table 89. Tianjin Yaowu Academe Pharmaceutical Industry Business Overview Table 90. Tianjin Yaowu Academe Pharmaceutical Industry Oral Anti-HBV Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Tianjin Yaowu Academe Pharmaceutical Industry Oral Anti-HBV Drugs Product Portfolio Table 92. Tianjin Yaowu Academe Pharmaceutical Industry Recent Development Table 93. Sichuan Kelun Pharmaceutical Company Information Table 94. Sichuan Kelun Pharmaceutical Business Overview Table 95. Sichuan Kelun Pharmaceutical Oral Anti-HBV Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. Sichuan Kelun Pharmaceutical Oral Anti-HBV Drugs Product Portfolio Table 97. Sichuan Kelun Pharmaceutical Recent Development Table 98. Shanghai Desano Pharmaceutical Company Information Table 99. Shanghai Desano Pharmaceutical Business Overview Table 100. Shanghai Desano Pharmaceutical Oral Anti-HBV Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. Shanghai Desano Pharmaceutical Oral Anti-HBV Drugs Product Portfolio Table 102. Shanghai Desano Pharmaceutical Recent Development Table 103. Qianjin Pharmaceutical Company Information Table 104. Qianjin Pharmaceutical Business Overview Table 105. Qianjin Pharmaceutical Oral Anti-HBV Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 106. Qianjin Pharmaceutical Oral Anti-HBV Drugs Product Portfolio Table 107. Qianjin Pharmaceutical Recent Development Table 108. Qilu Pharmaceutical Company Information Table 109. Qilu Pharmaceutical Business Overview Table 110. Qilu Pharmaceutical Oral Anti-HBV Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 111. Qilu Pharmaceutical Oral Anti-HBV Drugs Product Portfolio Table 112. Qilu Pharmaceutical Recent Development Table 113. Jiangxi Qingfeng Pharmaceutical Company Information Table 114. Jiangxi Qingfeng Pharmaceutical Business Overview Table 115. Jiangxi Qingfeng Pharmaceutical Oral Anti-HBV Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 116. Jiangxi Qingfeng Pharmaceutical Oral Anti-HBV Drugs Product Portfolio Table 117. Jiangxi Qingfeng Pharmaceutical Recent Development Table 118. Fujian Cosunter pharmaceutical Company Information Table 119. Fujian Cosunter pharmaceutical Business Overview Table 120. Fujian Cosunter pharmaceutical Oral Anti-HBV Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 121. Fujian Cosunter pharmaceutical Oral Anti-HBV Drugs Product Portfolio Table 122. Fujian Cosunter pharmaceutical Recent Development Table 123. Chengdu Brilliant Pharmaceutical Company Information Table 124. Chengdu Brilliant Pharmaceutical Business Overview Table 125. Chengdu Brilliant Pharmaceutical Oral Anti-HBV Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 126. Chengdu Brilliant Pharmaceutical Oral Anti-HBV Drugs Product Portfolio Table 127. Chengdu Brilliant Pharmaceutical Recent Development Table 128. Cisen Pharmaceutical Company Information Table 129. Cisen Pharmaceutical Business Overview Table 130. Cisen Pharmaceutical Oral Anti-HBV Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 131. Cisen Pharmaceutical Oral Anti-HBV Drugs Product Portfolio Table 132. Cisen Pharmaceutical Recent Development Table 133. Beijing SL Pharmaceutical Company Information Table 134. Beijing SL Pharmaceutical Business Overview Table 135. Beijing SL Pharmaceutical Oral Anti-HBV Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 136. Beijing SL Pharmaceutical Oral Anti-HBV Drugs Product Portfolio Table 137. Beijing SL Pharmaceutical Recent Development Table 138. Beijing Baiao Pharmaceutical Company Information Table 139. Beijing Baiao Pharmaceutical Business Overview Table 140. Beijing Baiao Pharmaceutical Oral Anti-HBV Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 141. Beijing Baiao Pharmaceutical Oral Anti-HBV Drugs Product Portfolio Table 142. Beijing Baiao Pharmaceutical Recent Development Table 143. Anhui Biochem Company Information Table 144. Anhui Biochem Business Overview Table 145. Anhui Biochem Oral Anti-HBV Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 146. Anhui Biochem Oral Anti-HBV Drugs Product Portfolio Table 147. Anhui Biochem Recent Development Table 148. Viatris Company Information Table 149. Viatris Business Overview Table 150. Viatris Oral Anti-HBV Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 151. Viatris Oral Anti-HBV Drugs Product Portfolio Table 152. Viatris Recent Development Table 153. Towa Pharmaceutical Company Information Table 154. Towa Pharmaceutical Business Overview Table 155. Towa Pharmaceutical Oral Anti-HBV Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 156. Towa Pharmaceutical Oral Anti-HBV Drugs Product Portfolio Table 157. Towa Pharmaceutical Recent Development Table 158. Teva Company Information Table 159. Teva Business Overview Table 160. Teva Oral Anti-HBV Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 161. Teva Oral Anti-HBV Drugs Product Portfolio Table 162. Teva Recent Development Table 163. Sigmapharm Laboratories Company Information Table 164. Sigmapharm Laboratories Business Overview Table 165. Sigmapharm Laboratories Oral Anti-HBV Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 166. Sigmapharm Laboratories Oral Anti-HBV Drugs Product Portfolio Table 167. Sigmapharm Laboratories Recent Development Table 168. Sandoz Pharmaceuticals Company Information Table 169. Sandoz Pharmaceuticals Business Overview Table 170. Sandoz Pharmaceuticals Oral Anti-HBV Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 171. Sandoz Pharmaceuticals Oral Anti-HBV Drugs Product Portfolio Table 172. Sandoz Pharmaceuticals Recent Development Table 173. GSK Company Information Table 174. GSK Business Overview Table 175. GSK Oral Anti-HBV Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 176. GSK Oral Anti-HBV Drugs Product Portfolio Table 177. GSK Recent Development Table 178. Gilead Sciences Company Information Table 179. Gilead Sciences Business Overview Table 180. Gilead Sciences Oral Anti-HBV Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 181. Gilead Sciences Oral Anti-HBV Drugs Product Portfolio Table 182. Gilead Sciences Recent Development Table 183. Camber Pharmaceuticals Company Information Table 184. Camber Pharmaceuticals Business Overview Table 185. Camber Pharmaceuticals Oral Anti-HBV Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 186. Camber Pharmaceuticals Oral Anti-HBV Drugs Product Portfolio Table 187. Camber Pharmaceuticals Recent Development Table 188. Bristol Myers Squibb Company Information Table 189. Bristol Myers Squibb Business Overview Table 190. Bristol Myers Squibb Oral Anti-HBV Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 191. Bristol Myers Squibb Oral Anti-HBV Drugs Product Portfolio Table 192. Bristol Myers Squibb Recent Development Table 193. Apotex Company Information Table 194. Apotex Business Overview Table 195. Apotex Oral Anti-HBV Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 196. Apotex Oral Anti-HBV Drugs Product Portfolio Table 197. Apotex Recent Development Table 198. Key Raw Materials Table 199. Raw Materials Key Suppliers Table 200. Oral Anti-HBV Drugs Distributors List Table 201. Oral Anti-HBV Drugs Customers List Table 202. Research Programs/Design for This Report Table 203. Authors List of This Report Table 204. Secondary Sources Table 205. Primary Sources List of Figures Figure 1. Oral Anti-HBV Drugs Product Image Figure 2. Global Oral Anti-HBV Drugs Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Oral Anti-HBV Drugs Sales Value (2021-2032) & (US$ Million) Figure 4. Global Oral Anti-HBV Drugs Sales (2021-2032) & (K Units) Figure 5. Global Oral Anti-HBV Drugs Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Oral Anti-HBV Drugs Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Adefovir Image Figure 10. Entecavir Image Figure 11. Lamivudine Image Figure 12. Telbivudine Image Figure 13. Tenofovir Image Figure 14. Other Image Figure 15. Global Oral Anti-HBV Drugs Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 16. Global Oral Anti-HBV Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 17. Global Oral Anti-HBV Drugs Sales Volume Share by Type (2021-2032) Figure 18. Global Oral Anti-HBV Drugs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Oral Anti-HBV Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 20. Global Oral Anti-HBV Drugs Sales Value Share by Type (2021-2032) Figure 21. Hospital and Clinic Image Figure 22. Pharmacy Image Figure 23. Other Image Figure 24. Global Oral Anti-HBV Drugs Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 25. Global Oral Anti-HBV Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 26. Global Oral Anti-HBV Drugs Sales Volume Share by Application (2021-2032) Figure 27. Global Oral Anti-HBV Drugs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 28. Global Oral Anti-HBV Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 29. Global Oral Anti-HBV Drugs Sales Value Share by Application (2021-2032) Figure 30. Global Oral Anti-HBV Drugs Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 31. Global Oral Anti-HBV Drugs Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 32. Global Oral Anti-HBV Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 33. Global Oral Anti-HBV Drugs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 34. North America Oral Anti-HBV Drugs Sales Value (2021-2032) & (US$ Million) Figure 35. North America Oral Anti-HBV Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Europe Oral Anti-HBV Drugs Sales Value (2021-2032) & (US$ Million) Figure 37. Europe Oral Anti-HBV Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Asia-Pacific Oral Anti-HBV Drugs Sales Value (2021-2032) & (US$ Million) Figure 39. Asia-Pacific Oral Anti-HBV Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 40. South America Oral Anti-HBV Drugs Sales Value (2021-2032) & (US$ Million) Figure 41. South America Oral Anti-HBV Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 42. Middle East & Africa Oral Anti-HBV Drugs Sales Value (2021-2032) & (US$ Million) Figure 43. Middle East & Africa Oral Anti-HBV Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 44. USA Oral Anti-HBV Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. USA Oral Anti-HBV Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. USA Oral Anti-HBV Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Canada Oral Anti-HBV Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Canada Oral Anti-HBV Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Canada Oral Anti-HBV Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Mexico Oral Anti-HBV Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Mexico Oral Anti-HBV Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Mexico Oral Anti-HBV Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Germany Oral Anti-HBV Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Germany Oral Anti-HBV Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Germany Oral Anti-HBV Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. France Oral Anti-HBV Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. France Oral Anti-HBV Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. France Oral Anti-HBV Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. U.K. Oral Anti-HBV Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. U.K. Oral Anti-HBV Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. U.K. Oral Anti-HBV Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Italy Oral Anti-HBV Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Italy Oral Anti-HBV Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Italy Oral Anti-HBV Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Spain Oral Anti-HBV Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Spain Oral Anti-HBV Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Spain Oral Anti-HBV Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Russia Oral Anti-HBV Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Russia Oral Anti-HBV Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Russia Oral Anti-HBV Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Netherlands Oral Anti-HBV Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Netherlands Oral Anti-HBV Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Netherlands Oral Anti-HBV Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. Nordic Countries Oral Anti-HBV Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. Nordic Countries Oral Anti-HBV Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. Nordic Countries Oral Anti-HBV Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. China Oral Anti-HBV Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. China Oral Anti-HBV Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. China Oral Anti-HBV Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Japan Oral Anti-HBV Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Japan Oral Anti-HBV Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Japan Oral Anti-HBV Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. South Korea Oral Anti-HBV Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. South Korea Oral Anti-HBV Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. South Korea Oral Anti-HBV Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. India Oral Anti-HBV Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. India Oral Anti-HBV Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. India Oral Anti-HBV Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Australia Oral Anti-HBV Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Australia Oral Anti-HBV Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Australia Oral Anti-HBV Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Southeast Asia Oral Anti-HBV Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Southeast Asia Oral Anti-HBV Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Southeast Asia Oral Anti-HBV Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Brazil Oral Anti-HBV Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Brazil Oral Anti-HBV Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Brazil Oral Anti-HBV Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Argentina Oral Anti-HBV Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Argentina Oral Anti-HBV Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Argentina Oral Anti-HBV Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Chile Oral Anti-HBV Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Chile Oral Anti-HBV Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Chile Oral Anti-HBV Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Colombia Oral Anti-HBV Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Colombia Oral Anti-HBV Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Colombia Oral Anti-HBV Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Peru Oral Anti-HBV Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Peru Oral Anti-HBV Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Peru Oral Anti-HBV Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Saudi Arabia Oral Anti-HBV Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Saudi Arabia Oral Anti-HBV Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Saudi Arabia Oral Anti-HBV Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Israel Oral Anti-HBV Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Israel Arabia Oral Anti-HBV Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Israel Arabia Oral Anti-HBV Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. UAE Oral Anti-HBV Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. UAE Oral Anti-HBV Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. UAE Oral Anti-HBV Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Turkey Oral Anti-HBV Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Turkey Oral Anti-HBV Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Turkey Oral Anti-HBV Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Iran Oral Anti-HBV Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Iran Oral Anti-HBV Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Iran Oral Anti-HBV Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Egypt Oral Anti-HBV Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 126. Egypt Oral Anti-HBV Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 127. Egypt Oral Anti-HBV Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 128. Oral Anti-HBV Drugs Value Chain Figure 129. Manufacturing Cost Structure Figure 130. Oral Anti-HBV Drugs Sales Mode & Process Figure 131. Direct Comparison with Distribution Share Figure 132. Distributors Profiles Figure 133. Years Considered Figure 134. Research Process Figure 135. Key Executives Interviewed

Scope & coverage.

Types
  • Adefovir
  • Entecavir
  • Lamivudine
  • Telbivudine
  • Tenofovir
  • Other
Applications
  • Hospital and Clinic
  • Pharmacy
  • Other
Companies covered
  • Zhongfu Pharmaceutical
  • Chia Tai Tianqing Pharmaceutical
  • Easton Biopharmaceuticals
  • YaoPharma
  • Tianjin Yaowu Academe Pharmaceutical Industry
  • Sichuan Kelun Pharmaceutical
  • Shanghai Desano Pharmaceutical
  • Qianjin Pharmaceutical
  • Qilu Pharmaceutical
  • Jiangxi Qingfeng Pharmaceutical
  • Fujian Cosunter pharmaceutical
  • Chengdu Brilliant Pharmaceutical
  • Cisen Pharmaceutical
  • Beijing SL Pharmaceutical
  • Beijing Baiao Pharmaceutical
  • Anhui Biochem
  • Viatris
  • Towa Pharmaceutical
  • Teva
  • Sigmapharm Laboratories
  • Sandoz Pharmaceuticals
  • GSK
  • Gilead Sciences
  • Camber Pharmaceuticals
  • Bristol Myers Squibb
  • Apotex

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Oral Anti-HBV Drugs Sales Value (2021-2032)
  4. 1.2.2 Global Oral Anti-HBV Drugs Sales Volume (2021-2032)
  5. 1.2.3 Global Oral Anti-HBV Drugs Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Oral Anti-HBV Drugs Market Dynamics
  1. 2.1 Oral Anti-HBV Drugs Industry Trends
  2. 2.2 Oral Anti-HBV Drugs Industry Drivers
  3. 2.3 Oral Anti-HBV Drugs Industry Opportunities and Challenges
  4. 2.4 Oral Anti-HBV Drugs Industry Restraints
3 Oral Anti-HBV Drugs Market by Company
  1. 3.1 Global Oral Anti-HBV Drugs Company Revenue Ranking in 2025
  2. 3.2 Global Oral Anti-HBV Drugs Revenue by Company (2021-2026)
  3. 3.3 Global Oral Anti-HBV Drugs Sales Volume by Company (2021-2026)
  4. 3.4 Global Oral Anti-HBV Drugs Average Price by Company (2021-2026)
  5. 3.5 Global Oral Anti-HBV Drugs Company Ranking (2024-2026)
  6. 3.6 Global Oral Anti-HBV Drugs Company Manufacturing Base and Headquarters
  7. 3.7 Global Oral Anti-HBV Drugs Company Product Type and Application
  8. 3.8 Global Oral Anti-HBV Drugs Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Oral Anti-HBV Drugs Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Oral Anti-HBV Drugs Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Oral Anti-HBV Drugs Market by Type
  1. 4.1 Oral Anti-HBV Drugs Type Introduction
  2. 4.1.1 Adefovir
  3. 4.1.2 Entecavir
  4. 4.1.3 Lamivudine
  5. 4.1.4 Telbivudine
  6. 4.1.5 Tenofovir
  7. 4.1.6 Other
  8. 4.2 Global Oral Anti-HBV Drugs Sales Volume by Type
  9. 4.2.1 Global Oral Anti-HBV Drugs Sales Volume by Type (2021 VS 2025 VS 2032)
  10. 4.2.2 Global Oral Anti-HBV Drugs Sales Volume by Type (2021-2032)
  11. 4.2.3 Global Oral Anti-HBV Drugs Sales Volume Share by Type (2021-2032)
  12. 4.3 Global Oral Anti-HBV Drugs Sales Value by Type
  13. 4.3.1 Global Oral Anti-HBV Drugs Sales Value by Type (2021 VS 2025 VS 2032)
  14. 4.3.2 Global Oral Anti-HBV Drugs Sales Value by Type (2021-2032)
  15. 4.3.3 Global Oral Anti-HBV Drugs Sales Value Share by Type (2021-2032)
5 Oral Anti-HBV Drugs Market by Application
  1. 5.1 Oral Anti-HBV Drugs Application Introduction
  2. 5.1.1 Hospital and Clinic
  3. 5.1.2 Pharmacy
  4. 5.1.3 Other
  5. 5.2 Global Oral Anti-HBV Drugs Sales Volume by Application
  6. 5.2.1 Global Oral Anti-HBV Drugs Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Oral Anti-HBV Drugs Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Oral Anti-HBV Drugs Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Oral Anti-HBV Drugs Sales Value by Application
  10. 5.3.1 Global Oral Anti-HBV Drugs Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Oral Anti-HBV Drugs Sales Value by Application (2021-2032)
  12. 5.3.3 Global Oral Anti-HBV Drugs Sales Value Share by Application (2021-2032)
6 Oral Anti-HBV Drugs Regional Sales and Value Analysis
  1. 6.1 Global Oral Anti-HBV Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Oral Anti-HBV Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Oral Anti-HBV Drugs Sales by Region: 2021-2026
  4. 6.2.2 Global Oral Anti-HBV Drugs Sales by Region (2027-2032)
  5. 6.3 Global Oral Anti-HBV Drugs Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Oral Anti-HBV Drugs Sales Value by Region (2021-2032)
  7. 6.4.1 Global Oral Anti-HBV Drugs Sales Value by Region: 2021-2026
  8. 6.4.2 Global Oral Anti-HBV Drugs Sales Value by Region (2027-2032)
  9. 6.5 Global Oral Anti-HBV Drugs Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Oral Anti-HBV Drugs Sales Value (2021-2032)
  12. 6.6.2 North America Oral Anti-HBV Drugs Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Oral Anti-HBV Drugs Sales Value (2021-2032)
  15. 6.7.2 Europe Oral Anti-HBV Drugs Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Oral Anti-HBV Drugs Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Oral Anti-HBV Drugs Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Oral Anti-HBV Drugs Sales Value (2021-2032)
  21. 6.9.2 South America Oral Anti-HBV Drugs Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Oral Anti-HBV Drugs Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Oral Anti-HBV Drugs Sales Value Share by Country, 2025 VS 2032
7 Oral Anti-HBV Drugs Country-level Sales and Value Analysis
  1. 7.1 Global Oral Anti-HBV Drugs Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Oral Anti-HBV Drugs Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Oral Anti-HBV Drugs Sales by Country (2021-2032)
  4. 7.3.1 Global Oral Anti-HBV Drugs Sales by Country (2021-2026)
  5. 7.3.2 Global Oral Anti-HBV Drugs Sales by Country (2027-2032)
  6. 7.4 Global Oral Anti-HBV Drugs Sales Value by Country (2021-2032)
  7. 7.4.1 Global Oral Anti-HBV Drugs Sales Value by Country (2021-2026)
  8. 7.4.2 Global Oral Anti-HBV Drugs Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Oral Anti-HBV Drugs Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Oral Anti-HBV Drugs Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Oral Anti-HBV Drugs Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Oral Anti-HBV Drugs Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Oral Anti-HBV Drugs Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Oral Anti-HBV Drugs Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Oral Anti-HBV Drugs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Oral Anti-HBV Drugs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Oral Anti-HBV Drugs Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Oral Anti-HBV Drugs Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Oral Anti-HBV Drugs Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Oral Anti-HBV Drugs Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Oral Anti-HBV Drugs Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Oral Anti-HBV Drugs Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Oral Anti-HBV Drugs Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Oral Anti-HBV Drugs Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Oral Anti-HBV Drugs Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Oral Anti-HBV Drugs Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Oral Anti-HBV Drugs Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Oral Anti-HBV Drugs Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Oral Anti-HBV Drugs Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Oral Anti-HBV Drugs Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Oral Anti-HBV Drugs Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Oral Anti-HBV Drugs Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Oral Anti-HBV Drugs Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Oral Anti-HBV Drugs Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Oral Anti-HBV Drugs Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Oral Anti-HBV Drugs Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Oral Anti-HBV Drugs Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Oral Anti-HBV Drugs Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Oral Anti-HBV Drugs Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Oral Anti-HBV Drugs Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Oral Anti-HBV Drugs Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Oral Anti-HBV Drugs Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Oral Anti-HBV Drugs Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Oral Anti-HBV Drugs Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Oral Anti-HBV Drugs Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Oral Anti-HBV Drugs Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Oral Anti-HBV Drugs Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Oral Anti-HBV Drugs Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Oral Anti-HBV Drugs Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Oral Anti-HBV Drugs Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Oral Anti-HBV Drugs Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Oral Anti-HBV Drugs Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Oral Anti-HBV Drugs Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Oral Anti-HBV Drugs Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Oral Anti-HBV Drugs Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Oral Anti-HBV Drugs Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Oral Anti-HBV Drugs Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Oral Anti-HBV Drugs Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Oral Anti-HBV Drugs Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Oral Anti-HBV Drugs Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Oral Anti-HBV Drugs Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Oral Anti-HBV Drugs Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Oral Anti-HBV Drugs Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Oral Anti-HBV Drugs Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Oral Anti-HBV Drugs Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Oral Anti-HBV Drugs Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Oral Anti-HBV Drugs Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Oral Anti-HBV Drugs Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Oral Anti-HBV Drugs Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Oral Anti-HBV Drugs Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Oral Anti-HBV Drugs Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Oral Anti-HBV Drugs Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Oral Anti-HBV Drugs Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Oral Anti-HBV Drugs Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Oral Anti-HBV Drugs Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Oral Anti-HBV Drugs Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Oral Anti-HBV Drugs Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Oral Anti-HBV Drugs Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Oral Anti-HBV Drugs Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Oral Anti-HBV Drugs Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Oral Anti-HBV Drugs Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Oral Anti-HBV Drugs Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Oral Anti-HBV Drugs Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Oral Anti-HBV Drugs Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Oral Anti-HBV Drugs Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Oral Anti-HBV Drugs Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Oral Anti-HBV Drugs Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Oral Anti-HBV Drugs Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Oral Anti-HBV Drugs Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Oral Anti-HBV Drugs Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Oral Anti-HBV Drugs Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Oral Anti-HBV Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Zhongfu Pharmaceutical
  2. 8.1.1 Zhongfu Pharmaceutical Company Information
  3. 8.1.2 Zhongfu Pharmaceutical Business Overview
  4. 8.1.3 Zhongfu Pharmaceutical Oral Anti-HBV Drugs Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Zhongfu Pharmaceutical Oral Anti-HBV Drugs Product Portfolio
  6. 8.1.5 Zhongfu Pharmaceutical Recent Developments
  7. 8.2 Chia Tai Tianqing Pharmaceutical
  8. 8.2.1 Chia Tai Tianqing Pharmaceutical Company Information
  9. 8.2.2 Chia Tai Tianqing Pharmaceutical Business Overview
  10. 8.2.3 Chia Tai Tianqing Pharmaceutical Oral Anti-HBV Drugs Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Chia Tai Tianqing Pharmaceutical Oral Anti-HBV Drugs Product Portfolio
  12. 8.2.5 Chia Tai Tianqing Pharmaceutical Recent Developments
  13. 8.3 Easton Biopharmaceuticals
  14. 8.3.1 Easton Biopharmaceuticals Company Information
  15. 8.3.2 Easton Biopharmaceuticals Business Overview
  16. 8.3.3 Easton Biopharmaceuticals Oral Anti-HBV Drugs Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Easton Biopharmaceuticals Oral Anti-HBV Drugs Product Portfolio
  18. 8.3.5 Easton Biopharmaceuticals Recent Developments
  19. 8.4 YaoPharma
  20. 8.4.1 YaoPharma Company Information
  21. 8.4.2 YaoPharma Business Overview
  22. 8.4.3 YaoPharma Oral Anti-HBV Drugs Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 YaoPharma Oral Anti-HBV Drugs Product Portfolio
  24. 8.4.5 YaoPharma Recent Developments
  25. 8.5 Tianjin Yaowu Academe Pharmaceutical Industry
  26. 8.5.1 Tianjin Yaowu Academe Pharmaceutical Industry Company Information
  27. 8.5.2 Tianjin Yaowu Academe Pharmaceutical Industry Business Overview
  28. 8.5.3 Tianjin Yaowu Academe Pharmaceutical Industry Oral Anti-HBV Drugs Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Tianjin Yaowu Academe Pharmaceutical Industry Oral Anti-HBV Drugs Product Portfolio
  30. 8.5.5 Tianjin Yaowu Academe Pharmaceutical Industry Recent Developments
  31. 8.6 Sichuan Kelun Pharmaceutical
  32. 8.6.1 Sichuan Kelun Pharmaceutical Company Information
  33. 8.6.2 Sichuan Kelun Pharmaceutical Business Overview
  34. 8.6.3 Sichuan Kelun Pharmaceutical Oral Anti-HBV Drugs Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Sichuan Kelun Pharmaceutical Oral Anti-HBV Drugs Product Portfolio
  36. 8.6.5 Sichuan Kelun Pharmaceutical Recent Developments
  37. 8.7 Shanghai Desano Pharmaceutical
  38. 8.7.1 Shanghai Desano Pharmaceutical Company Information
  39. 8.7.2 Shanghai Desano Pharmaceutical Business Overview
  40. 8.7.3 Shanghai Desano Pharmaceutical Oral Anti-HBV Drugs Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Shanghai Desano Pharmaceutical Oral Anti-HBV Drugs Product Portfolio
  42. 8.7.5 Shanghai Desano Pharmaceutical Recent Developments
  43. 8.8 Qianjin Pharmaceutical
  44. 8.8.1 Qianjin Pharmaceutical Company Information
  45. 8.8.2 Qianjin Pharmaceutical Business Overview
  46. 8.8.3 Qianjin Pharmaceutical Oral Anti-HBV Drugs Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Qianjin Pharmaceutical Oral Anti-HBV Drugs Product Portfolio
  48. 8.8.5 Qianjin Pharmaceutical Recent Developments
  49. 8.9 Qilu Pharmaceutical
  50. 8.9.1 Qilu Pharmaceutical Company Information
  51. 8.9.2 Qilu Pharmaceutical Business Overview
  52. 8.9.3 Qilu Pharmaceutical Oral Anti-HBV Drugs Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Qilu Pharmaceutical Oral Anti-HBV Drugs Product Portfolio
  54. 8.9.5 Qilu Pharmaceutical Recent Developments
  55. 8.10 Jiangxi Qingfeng Pharmaceutical
  56. 8.10.1 Jiangxi Qingfeng Pharmaceutical Company Information
  57. 8.10.2 Jiangxi Qingfeng Pharmaceutical Business Overview
  58. 8.10.3 Jiangxi Qingfeng Pharmaceutical Oral Anti-HBV Drugs Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Jiangxi Qingfeng Pharmaceutical Oral Anti-HBV Drugs Product Portfolio
  60. 8.10.5 Jiangxi Qingfeng Pharmaceutical Recent Developments
  61. 8.11 Fujian Cosunter pharmaceutical
  62. 8.11.1 Fujian Cosunter pharmaceutical Company Information
  63. 8.11.2 Fujian Cosunter pharmaceutical Business Overview
  64. 8.11.3 Fujian Cosunter pharmaceutical Oral Anti-HBV Drugs Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Fujian Cosunter pharmaceutical Oral Anti-HBV Drugs Product Portfolio
  66. 8.11.5 Fujian Cosunter pharmaceutical Recent Developments
  67. 8.12 Chengdu Brilliant Pharmaceutical
  68. 8.12.1 Chengdu Brilliant Pharmaceutical Company Information
  69. 8.12.2 Chengdu Brilliant Pharmaceutical Business Overview
  70. 8.12.3 Chengdu Brilliant Pharmaceutical Oral Anti-HBV Drugs Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Chengdu Brilliant Pharmaceutical Oral Anti-HBV Drugs Product Portfolio
  72. 8.12.5 Chengdu Brilliant Pharmaceutical Recent Developments
  73. 8.13 Cisen Pharmaceutical
  74. 8.13.1 Cisen Pharmaceutical Company Information
  75. 8.13.2 Cisen Pharmaceutical Business Overview
  76. 8.13.3 Cisen Pharmaceutical Oral Anti-HBV Drugs Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Cisen Pharmaceutical Oral Anti-HBV Drugs Product Portfolio
  78. 8.13.5 Cisen Pharmaceutical Recent Developments
  79. 8.14 Beijing SL Pharmaceutical
  80. 8.14.1 Beijing SL Pharmaceutical Company Information
  81. 8.14.2 Beijing SL Pharmaceutical Business Overview
  82. 8.14.3 Beijing SL Pharmaceutical Oral Anti-HBV Drugs Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 Beijing SL Pharmaceutical Oral Anti-HBV Drugs Product Portfolio
  84. 8.14.5 Beijing SL Pharmaceutical Recent Developments
  85. 8.15 Beijing Baiao Pharmaceutical
  86. 8.15.1 Beijing Baiao Pharmaceutical Company Information
  87. 8.15.2 Beijing Baiao Pharmaceutical Business Overview
  88. 8.15.3 Beijing Baiao Pharmaceutical Oral Anti-HBV Drugs Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 Beijing Baiao Pharmaceutical Oral Anti-HBV Drugs Product Portfolio
  90. 8.15.5 Beijing Baiao Pharmaceutical Recent Developments
  91. 8.16 Anhui Biochem
  92. 8.16.1 Anhui Biochem Company Information
  93. 8.16.2 Anhui Biochem Business Overview
  94. 8.16.3 Anhui Biochem Oral Anti-HBV Drugs Sales, Value and Gross Margin (2021-2026)
  95. 8.16.4 Anhui Biochem Oral Anti-HBV Drugs Product Portfolio
  96. 8.16.5 Anhui Biochem Recent Developments
  97. 8.17 Viatris
  98. 8.17.1 Viatris Company Information
  99. 8.17.2 Viatris Business Overview
  100. 8.17.3 Viatris Oral Anti-HBV Drugs Sales, Value and Gross Margin (2021-2026)
  101. 8.17.4 Viatris Oral Anti-HBV Drugs Product Portfolio
  102. 8.17.5 Viatris Recent Developments
  103. 8.18 Towa Pharmaceutical
  104. 8.18.1 Towa Pharmaceutical Company Information
  105. 8.18.2 Towa Pharmaceutical Business Overview
  106. 8.18.3 Towa Pharmaceutical Oral Anti-HBV Drugs Sales, Value and Gross Margin (2021-2026)
  107. 8.18.4 Towa Pharmaceutical Oral Anti-HBV Drugs Product Portfolio
  108. 8.18.5 Towa Pharmaceutical Recent Developments
  109. 8.19 Teva
  110. 8.19.1 Teva Company Information
  111. 8.19.2 Teva Business Overview
  112. 8.19.3 Teva Oral Anti-HBV Drugs Sales, Value and Gross Margin (2021-2026)
  113. 8.19.4 Teva Oral Anti-HBV Drugs Product Portfolio
  114. 8.19.5 Teva Recent Developments
  115. 8.20 Sigmapharm Laboratories
  116. 8.20.1 Sigmapharm Laboratories Company Information
  117. 8.20.2 Sigmapharm Laboratories Business Overview
  118. 8.20.3 Sigmapharm Laboratories Oral Anti-HBV Drugs Sales, Value and Gross Margin (2021-2026)
  119. 8.20.4 Sigmapharm Laboratories Oral Anti-HBV Drugs Product Portfolio
  120. 8.20.5 Sigmapharm Laboratories Recent Developments
  121. 8.21 Sandoz Pharmaceuticals
  122. 8.21.1 Sandoz Pharmaceuticals Company Information
  123. 8.21.2 Sandoz Pharmaceuticals Business Overview
  124. 8.21.3 Sandoz Pharmaceuticals Oral Anti-HBV Drugs Sales, Value and Gross Margin (2021-2026)
  125. 8.21.4 Sandoz Pharmaceuticals Oral Anti-HBV Drugs Product Portfolio
  126. 8.21.5 Sandoz Pharmaceuticals Recent Developments
  127. 8.22 GSK
  128. 8.22.1 GSK Company Information
  129. 8.22.2 GSK Business Overview
  130. 8.22.3 GSK Oral Anti-HBV Drugs Sales, Value and Gross Margin (2021-2026)
  131. 8.22.4 GSK Oral Anti-HBV Drugs Product Portfolio
  132. 8.22.5 GSK Recent Developments
  133. 8.23 Gilead Sciences
  134. 8.23.1 Gilead Sciences Company Information
  135. 8.23.2 Gilead Sciences Business Overview
  136. 8.23.3 Gilead Sciences Oral Anti-HBV Drugs Sales, Value and Gross Margin (2021-2026)
  137. 8.23.4 Gilead Sciences Oral Anti-HBV Drugs Product Portfolio
  138. 8.23.5 Gilead Sciences Recent Developments
  139. 8.24 Camber Pharmaceuticals
  140. 8.24.1 Camber Pharmaceuticals Company Information
  141. 8.24.2 Camber Pharmaceuticals Business Overview
  142. 8.24.3 Camber Pharmaceuticals Oral Anti-HBV Drugs Sales, Value and Gross Margin (2021-2026)
  143. 8.24.4 Camber Pharmaceuticals Oral Anti-HBV Drugs Product Portfolio
  144. 8.24.5 Camber Pharmaceuticals Recent Developments
  145. 8.25 Bristol Myers Squibb
  146. 8.25.1 Bristol Myers Squibb Company Information
  147. 8.25.2 Bristol Myers Squibb Business Overview
  148. 8.25.3 Bristol Myers Squibb Oral Anti-HBV Drugs Sales, Value and Gross Margin (2021-2026)
  149. 8.25.4 Bristol Myers Squibb Oral Anti-HBV Drugs Product Portfolio
  150. 8.25.5 Bristol Myers Squibb Recent Developments
  151. 8.26 Apotex
  152. 8.26.1 Apotex Company Information
  153. 8.26.2 Apotex Business Overview
  154. 8.26.3 Apotex Oral Anti-HBV Drugs Sales, Value and Gross Margin (2021-2026)
  155. 8.26.4 Apotex Oral Anti-HBV Drugs Product Portfolio
  156. 8.26.5 Apotex Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Oral Anti-HBV Drugs Value Chain Analysis
  2. 9.1.1 Oral Anti-HBV Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Oral Anti-HBV Drugs Sales Mode & Process
  6. 9.2 Oral Anti-HBV Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Oral Anti-HBV Drugs Distributors
  9. 9.2.3 Oral Anti-HBV Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst